SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Pfizer
Pfizer
Page 37 of 37
Pfizer admits to potential job losses in AstraZeneca takeover
By
Laura Lorenzetti
May 13, 2014
Finance
Pfizer prepares to woo U.K. lawmakers in bid for rival AstraZeneca
By
Laura Lorenzetti
May 12, 2014
AstraZeneca shares climb in hopes of bigger Pfizer offer
By
Laura Lorenzetti
May 9, 2014
Finance
Pfizer’s massive tax play for AstraZeneca
By
Cyrus Sanati
April 29, 2014
Management
Behind Pfizer’s latest upheaval at the top
By
Patricia Sellers
December 17, 2013
Features
Inside Pfizer’s palace coup
By
Peter Elkind
and
Jennifer Reingold
July 28, 2011
Pfizer wins big Celebrex ruling
By
Roger Parloff
November 20, 2007
Supreme Court takes case with big stakes for Vioxx suits
By
Roger Parloff
September 27, 2007
Most Popular
Banking
Markets expected the rate cut, but the ‘real surprise’ is the Fed’s opinion on the current state of the economy, quant...
By
Amanda Gerut
Law
Publishers Clearing House, company that promised 'forever' payments to sweepstakes winners, says actually nevermind
By
The Associated Press
Economy
The economy is reliant on the 'fortunes of the well-to-do' says Moody's—if the ultra-rich get nervy that means recession
By
Eleanor Pringle
